


PHARMACEUTICAL 2022

abbvie

AbbVie Inc. Rank 28 of 475







RealRate

PHARMACEUTICAL 2022

AbbVie Inc. Rank 28 of 475



The relative strengths and weaknesses of AbbVie Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AbbVie Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 309% points. The greatest weakness of AbbVie Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 187%, being 463% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	27,928,000
Cost of Goods Sold	17,446,000
Intangible Assets	108,330,000
Liabilities, Current	35,194,000
Liabilities, Non-Current	0
Other Assets	5,161,000
Other Compr. Net Income	211,000
Other Expenses	1,872,000
Other Liabilities	0
Other Net Income	-4,935,000
Property and Equipment	5,110,000
Research and Development	8,046,000
Revenues	56,197,000
Selling, General and Administrative Expense	12,349,000

Output Variable	Value in 1000 USD
Assets	146,529,000
Liabilities	35,194,000
Expenses	39,713,000
Stockholders Equity	111,335,000
Net Income	11,549,000
Comprehensive Net Income	11,654,500
Economic Capital Ratio	187%

